This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Weibel, R. E.
Right arrow Articles by Evans, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Weibel, R. E.
Right arrow Articles by Evans, G.
Related Collections
Right arrow Infectious Disease & Immunity
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

PEDIATRICS Vol. 101 No. 3 March 1998, pp. 383-387

Acute Encephalopathy Followed by Permanent Brain Injury or Death Associated With Further Attenuated Measles Vaccines: A Review of Claims Submitted to the National Vaccine Injury Compensation Program

Received Jul 30, 1997; accepted Sep 23, 1997.

Robert E. Weibel*, Vito Caserta*, David E. BenorDagger , and Geoffrey Evans*

From the * Division of Vaccine Injury Compensation, National Vaccine Injury Compensation Program, Health Resources and Services Administration, Public Health Service, Rockville, Maryland; and the Dagger  Office of the General Counsel, United States Department of Health and Human Services, Rockville, Maryland.

Objective.  To determine if there is evidence for a causal relationship between acute encephalopathy followed by permanent brain injury or death associated with the administration of further attenuated measles vaccines (Attenuvax or Lirugen, Hoechst Marion Roussel, Kansas City, MO), mumps vaccine (Mumpsvax, Merck and Co, Inc, West Point, PA), or rubella vaccines (Meruvax or Meruvax II, Merck and Co, Inc, West Point, PA), combined measles and rubella vaccine (M-R-Vax or M-R-Vax II, Merck and Co, Inc, West Point, PA), or combined measles, mumps, and rubella vaccine (M-M-R or M-M-R II, Merck and Co, Inc, West Point, PA), the lead author reviewed claims submitted to the National Vaccine Injury Compensation Program.

Methods.  The medical records of children who met the inclusion criteria of receiving the first dose of these vaccines between 1970 and 1993 and who developed such an encephalopathy with no determined cause within 15 days were identified and analyzed.

Results.  A total of 48 children, ages 10 to 49 months, met the inclusion criteria after receiving measles vaccine, alone or in combination. Eight children died, and the remainder had mental regression and retardation, chronic seizures, motor and sensory deficits, and movement disorders. The onset of neurologic signs or symptoms occurred with a nonrandom, statistically significant distribution of cases on days 8 and 9. No cases were identified after the administration of monovalent mumps or rubella vaccine.

Conclusions.  This clustering suggests that a causal relationship between measles vaccine and encephalopathy may exist as a rare complication of measles immunization.

Key words: measles vaccine, encephalopathy, encephalitis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 PediatricsHome page
K. N. Ward, N. J. Bryant, N. J. Andrews, J. S. Bowley, A. Ohrling, C. M. Verity, E. M. Ross, and E. Miller
Risk of Serious Neurologic Disease After Immunization of Young Children in Britain and Ireland
Pediatrics, August 1, 2007; 120(2): 314 - 321.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
K. Aydon, S. Elmas, and E. A. Guzes
Reversible Posterior Leukoencephalopathy and Adie's Pupil After Measles Vaccination
J Child Neurol, June 1, 2006; 21(6): 525 - 527.
[Abstract] [PDF]

Home page
 PediatricsHome page
A. Makela, J. P. Nuorti, and H. Peltola
Neurologic Disorders After Measles-Mumps-Rubella Vaccination
Pediatrics, November 1, 2002; 110(5): 957 - 963.
[Abstract] [Full Text] [PDF]

Home page
 Clin Child Psychol PsychiatryHome page
K. Yazbak
The New Autism: One Family's Perspective
Clinical Child Psychology and Psychiatry, October 1, 2002; 7(4): 505 - 517.
[PDF]

Home page
 Clin Child Psychol PsychiatryHome page
A. J. Wakefield
Commentary on 'The New Autism': One Family's Perspective
Clinical Child Psychology and Psychiatry, October 1, 2002; 7(4): 518 - 524.
[PDF]

Home page
 NEJMHome page
G. Ada
Vaccines and Vaccination
N. Engl. J. Med., October 4, 2001; 345(14): 1042 - 1053.
[Full Text] [PDF]

Home page
 NeurologyHome page
G. M. Fenichel
Assessment: Neurologic risk of immunization: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology
Neurology, May 1, 1999; 52(8): 1546 - 1546.
[Full Text] [PDF]

Home page
 PediatricsHome page
S. Sepkowitz;, G. Preiser;, R. E. Weibel, V. Caserta, D. E. Benor, and G. Evans
Polio Vaccine and Polio
Pediatrics, March 1, 1999; 103(3): 694a - 696.
[Full Text]

Home page
 Arch Pediatr Adolesc MedHome page
G. Evans
Vaccine Liability and Safety Revisited
Arch Pediatr Adolesc Med, January 1, 1998; 152(1): 7 - 10.
[Full Text] [PDF]